Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
ZT-002 by Beijing QL Biopharmaceutical for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
ZT-002 is under clinical development by Beijing QL Biopharmaceutical and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According...